tbuckley/cabot-search huggingface dataset:
Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study
Authors: Noopur Raje, Ian Chau, David M. Hyman, Vincent Ribrag, Jean-Yves Blay, Josep Tabernero, Maria Elena Elez-Fernandez, Jürgen S. Wolf, Florin Sirzen, Andrew Yee, Jason Faris, Martin Kaiser, Heather Landau, Jean-Marie Michot, Luisa Veronese, Martina Makrutzki, Susan Francis Lasserre, Igor Puzanov, Jose Baselga
Journal: Blood (2015)
Unmeasurable Serum M-Protein Multiple Myeloma Benefit Less from Bortezomib Than Measurable Myeloma
Authors: Xiaoqi Qin, Gang An, Yan Xu, Yu Qin, Xiaoyan Feng, Meirong Zang, Weiwei Sui, Shuhui Deng, Shuhua Yi, Wen Zhou, Lugui Qiu
Journal: Blood (2014)
Cross-activity analyses of standard chemotherapy regimens for primary breast cancer using the ATP-based tumor chemosensitivity assay: Pharmacoeconomic implications.
Authors: C. M. Kurbacher, P. N. Arenz, R. Reichelt
Journal: Journal of Clinical Oncology (2010)

e11033 Background: Chemotherapy (Ctx) for primary breast cancer (PBC) now utilizes expensive drugs, thus emerging important pharmacoecomic implications. This study was initiated to analyze the cross-activity of standard Ctx regimens (Ctx-R) in PBC using the ex vivo ATP-based tumor chemosensitivity assay (ATP-TCA). Methods: Eight Ctx-R were studied in a total of 96 native PBCs: epirubicin (EPI); mitoxantrone (MX); paclitaxel (PCT); docetaxel (DCT); CMF, 4-OH-cyclophosphamide (4-HC) + methotrexate (MTX) + 5-fluorouracil (5-FU); EC, EPI+4-HC; ET, EPI+PCT; NT, MX+PCT. Each Ctx-R was tested at a 1.5 log dose range. Using a semi-quantitative score, individual chemosensitivity score was classified as complete, incomplete, or resistance. Eight head-to-head comparisons were made: CMF versus EC, n = 56; CMF versus PCT, n = 49; CMF versus DCT, n = 34; EC versus PCT, n = 51; EC versus DCT, n = 35; EC versus ET, n = 45; ET versus NT, n = 24; PCT versus DCT, n = 34. For every comparison, the assumed cost reduction if using ATP-TCA directed Ctx was calculated for the tested population regarding the current German prices for both Ctx and supportive drugs and the costs for the ATP-TCA. Results: CMF was at least equal to EC in 47 (84%), to PCT in 37 (76%), and to DCT in 29 PBCs (86%). EC was at least equal to PCT in 41 (80%), to DCT in 28 (80%), and to ET in 28 PBCs (62%). NT was at least equal to ET in 47 PBCs (79%), and PCT was at least equal to DCT in 27 PBCs (80%). The calculated potential cost reduction by ATP-TCA directed Ctx ranged between € 457 (PCT vs. DCT) and € 18.847 (CMF vs. DCT) per treatment. Regarding the whole study population, the potential cost reduction ranged between € 2.550 (PCT vs. DCT) and € 611.819 (CMF vs. DCT). Conclusions: These results are in good agreement to clinical studies showing that novel Ctx-R will benefit only a limited proportion of PBC patients. Systematic analyses using biological methods like the ATP-TCA could help to identify individual patients who are likely to benefit from these Ctx-R whereas the remainder could be equally subjected to less toxic or less costly regimens. Depending on the particular comparison made in this study, the use of the ATP-TCA could lead to a considerable cost reduction in Ctx for PBC. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration L.a.n.c.e. mbH L.a.n.c.e. mbH
Histoacryl injection for treatment of varices in the ascending colon
Authors: Mafalda Sousa, Iolanda Ribeiro, Luísa Proença, Joana Silva, Ana Ponte, Jaime Rodrigues
Journal: Endoscopy (2016)

A 50-year-old man with alcoholic liver cirrhosis was admitted to our emergency department with massive hematochezia and hypovolemic shock. On admission, laboratory data included hemoglobin 3.1 g/dL, hematocrit 9.9 %, platelet count 81 × 109/L, lactates 13.9 mmol/L, and international normalized ratio 1.29. Resuscitation was initiated with intravenous fluids and transfusion of 4 units of packed red blood cells. Terlipressin 2 mg and ceftriaxone 1 g were administered.
Clinical Significance of Co-Expression of MYC and BCL2 Protein in Advanced Diffuse Large B-Cell Lymphoma Treated with a Dose-Intensified Immunochemotherapy
Authors: Hiromichi Takahashi, Sumiko Kobayashi, Katsuhiro Miura, Daisuke Kurita, Yoshihiro Hatta, Masahiko Sugitani, Shimon Otake, Masaru Nakagawa, Masashi Sakagami, Yoshihito Uchino, Hitomi Kodaira, Noriyoshi Iriyama, Machiko Kusuda, Atsuko Hojo, Mai Yagi, Yukio Hirabayashi, Yujin Kobayashi, Tomohiro Nakayama, Masami Takei
Journal: Blood (2015)
Standard vs Distal Roux-en-Y Gastric Bypass in Patients With Body Mass Index 50 to 60
Authors: Hilde Risstad, Marius Svanevik, Jon A. Kristinsson, Jøran Hjelmesæth, Erlend T. Aasheim, Dag Hofsø, Torgeir T. Søvik, Tor-Ivar Karlsen, Morten W. Fagerland, Rune Sandbu, Tom Mala
Journal: JAMA Surgery (2016)

Up to one-third of patients undergoing bariatric surgery have a body mass index (BMI) of more than 50. Following standard gastric bypass, many of these patients still have a BMI greater than 40 after peak weight loss.To assess the efficacy and safety of standard gastric bypass vs distal gastric bypass in patients with a BMI of 50 to 60.Double-blind, randomized clinical parallel-group trial at 2 tertiary care centers in Norway (Oslo University Hospital and Vestfold Hospital Trust) between May 2011 and April 2013. The study included 113 patients with a BMI of 50 to 60 aged 20 to 60 years. The 2-year follow-up was completed in May 2015.Standard gastric bypass (alimentary limb, 150 cm) and distal gastric bypass (common channel, 150 cm), both with a biliopancreatic limb of 50 cm and a gastric pouch of about 25 mL.Primary outcome was the change in BMI from baseline until 2 years after surgery. Secondary outcomes were cardiometabolic risk factors, nutritional outcomes, adverse events, gastrointestinal symptoms, and health-related quality of life.At baseline, the mean age of the patients was 40 years (95% CI, 38-41 years), 65% were women, mean BMI was 53.5 (95% CI, 52.9-54.0), and mean weight was 158.8 kg (95% CI, 155.3-162.3 kg). The mean reduction in BMI was 17.8 (95% CI, 16.9-18.6) after standard gastric bypass and 17.2 (95% CI, 16.3-18.0) after distal gastric bypass, and the mean between-group difference was 0.6 (95% CI, -0.6 to 1.8; P = .32). Reductions in mean levels of total and low-density lipoprotein cholesterol were greater after distal gastric bypass than standard gastric bypass, and between-group differences were 19 mg/dL (95% CI, 11-27 mg/dL ) and 28 mg/dL (95% CI, 21 to 34 mg/dL), respectively (P < .001 for both). Reductions in fasting glucose levels and hemoglobin A1c were greater after distal gastric bypass. Secondary hyperparathyroidism and loose stools were more frequent after distal gastric bypass. The number of adverse events and changes in health-related quality of life did not differ between the groups. Importantly, 1 patient developed liver failure and 2 patients developed protein-caloric malnutrition treated by elongation of the common channel following distal gastric bypass.Distal gastric bypass was not associated with a greater BMI reduction than standard gastric bypass 2 years after surgery. However, we observed different changes in cardiometabolic risk factors and nutritional markers between the groups.Clinicaltrials.gov Identifier: NCT00821197.
Prognostic RNAs in oesophageal squamous cell carcinoma: small is beautiful
Authors: Patrick Tan, Russell Petty
Journal: Gut (2016)

Oesophageal cancer is a deadly malignancy and is highly heterogeneous at the histological, geographical and molecular levels. It is broadly divided into adenocarcinomas and oesophageal squamous cell carcinomas (OSCCs). OSCCs are particularly prevalent in Asia and Africa where the disease has been linked to tobacco smoking, alcohol consumption and population-specific genetic risk variants.1 Clinically, oesophagectomy is the standard of care for curative therapy, usually proceeded by neoadjuvant chemotherapy/concurrent chemoradiotherapy, or in some cases definitive chemoradiotherapy without surgery. Unfortunately, the majority of patients with OSCC will relapse, and many either present too late or are too frail for curative treatment, resulting in an overall 5-year survival rate of 20%. Recent genomic studies have revealed a plethora of genetic alterations in OSCC, including mutations in TP53 , PIK3CA and chromatin modifier genes.2–4 Robust approaches are thus needed for accurately subtyping patients with OSCC, to tailor existing therapies and to identify subtype-specific driver alterations that may highlight opportunities for novel interventions. Interestingly, several genomic alterations in OSCC are also observed in squamous carcinomas from other body sites, including the lung.

Previous studies applying molecular profiling to predict prognosis of patients with OSCC have suffered from limitations challenging their widespread clinical applicability.5 ,6 These include the lack of demonstrated validation in multiple independent cohorts from different patient populations, and a requirement to measure large numbers of genes to achieve accurate classification. Technical challenges also exist, particularly in …
Zika Virus Is More Like Rubella Than Human Immunodeficiency Virus—Reply
Authors: Peter J. Hotez
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Hyperthermia for Major Depressive Disorder?
Authors: Michael Berk, Susannah Tye, Ken Walder, Sean McGee
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
The dark side of the moon: AKT as a tumor suppressor in the liver?
Authors: Xin Chen, Diego F. Calvisi
Journal: Hepatology (2016)

1Department of Bioengineering and Therapeutic Sciences and Liver CenterUniversity of CaliforniaSan FranciscoCA 2Institute of PathologyUniversity of GreifswaldGreifswaldGermany 3Department of Clinical and Experimental MedicineUniversity of SassariSassariItaly
Amplification of clinical benefit at six months with the glycoprotein IIb/IIIa inhibitor lamifiban in patients with non ST segment elevation in acute coronary syndromes
Authors: RA Harrington, DJ Moliterno, LK Newby, PW Armstrong, Frans Van de Werf, J Simes, A Rames, MV Bhapkar, RM Califf, A Keech, EJ Topol
Journal: Circulation (1997)
Reply to Marcus V. Cronauer, Axel S. Merseburger, and M. Raschid Hoda's Letter to the Editor re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol 2017;71:1–3
Authors: Julie Steinestel, Christof Bernemann, Andres J. Schrader, Jochen K. Lennerz
Journal: European Urology (2016)
Like a Garment
Authors: Carol Snyder Halberstadt
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Breaking down brain barrier breaches in cerebral malaria
Authors: Jens E.V. Petersen, Thomas Lavstsen, Alister Craig
Journal: Journal of Clinical Investigation (2016)

Recent findings have linked brain swelling to death in cerebral malaria (CM). These observations have prompted a number of investigations into the mechanisms of this pathology with the goal of identifying potential therapeutic targets. In this issue of the JCI, Gallego-Delgado and colleagues present evidence that implicates angiotensin receptors and the relocation of β-catenin to the endothelial cell nucleus in CM. This study provides a renewed focus on infected erythrocyte debris as the cause of endothelial damage and challenges previous work implicating direct effects of infected erythrocyte sequestration in the brain as the major driver of disease. While this work provides potential therapeutic avenues for CM, it leaves a number of questions unanswered.
P3-183: Analysis of predictive factors for radiation esophagitis by concurrent chemoradiation in lung cancer patients
Authors: Hidemasa Kawamura, Takeshi Ebara, Tetsuo Nonaka, Hitoshi Ishikawa, Hiroki Kiyohara, Masaru Wakatsuki, Hideyuki Sakurai, Takashi Nakano
Journal: Journal of Thoracic Oncology (2007)
Reply to Eugenio Ventimiglia, Francesco Montorsi, and Andrea Salonia's Letter to the Editor re: Jakob Damsgaard, Ulla N. Joensen, Elisabeth Carlsen, et al. Varicocele Is Associated with Impaired Semen Quality and Reproductive Hormone Levels: A Study of 7035 Healthy Young Men from Six European Countries. Eur Urol 2016;70:1019–29
Authors: Jakob Damsgaard, Ulla N. Joensen, Elisabeth Carlsen, Juris Erenpreiss, Martin Blomberg Jensen, Valentinas Matulevicius, Birute Zilaitiene, Inge A. Olesen, Antti Perheentupa, Margus Punab, Andrea Salzbrunn, Jorma Toppari, Helena E. Virtanen, Anders Juul, Niels E. Skakkebæk, Niels Jørgensen
Journal: European Urology (2016)
Lactate Dehydrogenase B Controls Lysosome Activity and Autophagy in Cancer
Authors: Lucie Brisson, Piotr Bański, Martina Sboarina, Coralie Dethier, Pierre Danhier, Marie-Joséphine Fontenille, Vincent F. Van Hée, Thibaut Vazeille, Morgane Tardy, Jorge Falces, Caroline Bouzin, Paolo E. Porporato, Raphaël Frédérick, Carine Michiels, Tamara Copetti, Pierre Sonveaux
Journal: Cancer Cell (2016)
P3-053: Factors affecting the local curability of cryoablation for malignant pulmonary tumors
Authors: Masafumi Kawamura, Yotaro Izumi, Norimasa Tukada, Keisuke Asakura, Koichi Kobayashi, Hideki Yashiro, Seishi Nakatsuka, Sachio Kuribayashi
Journal: Journal of Thoracic Oncology (2007)
Treatment Outcomes in Multidrug-Resistant Tuberculosis
Authors: Gunar Günther, Christoph Lange, Sofia Alexandru, Neus Altet, Korkut Avsar, Didi Bang, Raisa Barbuta, Graham Bothamley, Ana Ciobanu, Valeriu Crudu, Manfred Danilovits, Martin Dedicoat, Raquel Duarte, Gina Gualano, Heinke Kunst, Wiel de Lange, Vaira Leimane, Cecile Magis-Escurra, Anne-Marie McLaughlin, Inge Muylle, Veronika Polcová, Christina Popa, Rudolf Rumetshofer, Alena Skrahina, Varvara Solodovnikova, Victor Spinu, Simon Tiberi, Piret Viiklepp, Frank van Leth
Journal: New England Journal of Medicine (2016)

Multidrug-resistant tuberculosis is a major global challenge. This report examines the definition of treatment success and its effect on determining cure.
Pharmacokinetically Targeted Intravenous Busulfan Combined with Fludarabine (BuFlu) as Conditioning Prior to Allogeneic Peripheral Blood Hematopoietic Cell Transplant: Pretransplant Predictors of Outcomes.
Authors: Janelle Perkins, Jongphil Kim, Claudio Anasetti, Mohamed A Kharfan-Dabaja, Ernesto Ayala, Lia Perez, Hugo Fernandez, Karen Fancher, Cheryl Tate, Teresa Field
Journal: Blood (2009)
P2-290: Phase II study of S-1 in non-small cell lung cancer (NSCLC) patients previously treated with a platinum-based regimen
Authors: Hiroshi Nokihara, Shunji Nagai, Terufumi Kato, Fumiaki Koizumi, Kazuto Nishio, Noboru Yamamoto, Ikuo Sekine, Hideo Kunitoh, Yuichiro Ohe, Tomohide Tamura
Journal: Journal of Thoracic Oncology (2007)
Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study
Authors: James C. Yao, Marianne Pavel, Catherine Lombard-Bohas, Eric Van Cutsem, Maurizio Voi, Ulrike Brandt, Wei He, David Chen, Jaume Capdevila, Elisabeth G.E. de Vries, Paola Tomassetti, Timothy Hobday, Rodney Pommier, Kjell Öberg
Journal: Journal of Clinical Oncology (2016)

Purpose Everolimus improved median progression-free survival by 6.4 months in patients with advanced pancreatic neuroendocrine tumors (NET) compared with placebo in the RADIANT-3 study. Here, we present the final overall survival (OS) data and data on the impact of biomarkers on OS from the RADIANT-3 study. Methods Patients with advanced, progressive, low- or intermediate-grade pancreatic NET were randomly assigned to everolimus 10 mg/day (n = 207) or placebo (n = 203). Crossover from placebo to open-label everolimus was allowed on disease progression. Ongoing patients were unblinded after final progression-free survival analysis and could transition to open-label everolimus at the investigator’s discretion (extension phase). OS analysis was performed using a stratified log-rank test in the intent-to-treat population. The baseline levels of chromogranin A, neuron-specific enolase, and multiple soluble angiogenic biomarkers were determined and their impact on OS was explored. Results Of 410 patients who were enrolled between July 2007 and March 2014, 225 received open-label everolimus, including 172 patients (85%) randomly assigned initially to the placebo arm. Median OS was 44.0 months (95% CI, 35.6 to 51.8 months) for those randomly assigned to everolimus and 37.7 months (95% CI, 29.1 to 45.8 months) for those randomly assigned to placebo (hazard ratio, 0.94; 95% CI, 0.73 to 1.20; P = .30). Elevated baseline chromogranin A, neuron-specific enolase, placental growth factor, and soluble vascular endothelial growth factor receptor 1 levels were poor prognostic factors for OS. The most common adverse events included stomatitis, rash, and diarrhea. Conclusion Everolimus was associated with a median OS of 44 months in patients with advanced, progressive pancreatic NET, the longest OS reported in a phase III study for this population. Everolimus was associated with a survival benefit of 6.3 months, although this finding was not statistically significant. Crossover of patients likely confounded the OS results.
mTORC1 and mTORC2 Kinase Signaling and Glucose Metabolism Drive Follicular Helper T Cell Differentiation
Authors: Hu Zeng, Sivan Cohen, Cliff Guy, Sharad Shrestha, Geoffrey Neale, Scott A. Brown, Caryn Cloer, Rigel J. Kishton, Xia Gao, Ben Youngblood, Mytrang Do, Ming O. Li, Jason W. Locasale, Jeffrey C. Rathmell, Hongbo Chi
Journal: Immunity (2016)
PKA regulatory IIα subunit is essential for PGD2-mediated resolution of inflammation
Authors: Deping Kong, Yujun Shen, Guizhu Liu, Shengkai Zuo, Yong Ji, Ankang Lu, Masataka Nakamura, Michael Lazarus, Constantine A. Stratakis, Richard M. Breyer, Ying Yu
Journal: The Journal of Experimental Medicine (2016)

The kinetic participation of macrophages is critical for inflammatory resolution and recovery from myocardial infarction (MI), particularly with respect to the transition from the M1 to the M2 phenotype; however, the underlying mechanisms are poorly understood. In this study, we found that the deletion of prostaglandin (PG) D2 receptor subtype 1 (DP1) in macrophages retarded M2 polarization, antiinflammatory cytokine production, and resolution in different inflammatory models, including the MI model. DP1 deletion up-regulated proinflammatory genes expression via JAK2/STAT1 signaling in macrophages, whereas its activation facilitated binding of the separated PKA regulatory IIα subunit (PRKAR2A) to the transmembrane domain of IFN-γ receptor, suppressed JAK2-STAT1 axis-mediated M1 polarization, and promoted resolution. PRKAR2A deficiency attenuated DP1 activation-mediated M2 polarization and resolution of inflammation. Collectively, PGD2-DP1 axis-induced M2 polarization facilitates resolution of inflammation through the PRKAR2A-mediated suppression of JAK2/STAT1 signaling. These observations indicate that macrophage DP1 activation represents a promising strategy in the management of inflammation-associated diseases, including post-MI healing.
Patient and rheumatologist perspectives on glucocorticoids an exercise to improve the implementation of the EULAR recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases
Authors: M C Van der Goes, J Wg Jacobs, M Boers, T Andrews, M Am Blom-Bakkers, F Buttgereit, N Caeyers, E H Choy, M Cutolo, J Ap Da Silva, L Guillevin, M Holland, J R Kirwan, J Rovensky, K G Saag, G Severijns, S Webber, Rene Westhovens, J Wj Bijlsma
Journal: Annals of the Rheumatic Diseases (2010)